IFNBInternational Federation of Naked Bodybuilding
IFNBIntermediarios Financieros No Bancarios (Spanish: Non-Bank Financial Intermediaries)
IFNBInstituciones Financieras No Bancarias (Spanish: Non-Bank Financial Institutions; economics)
References in periodicals archive ?
Similarly, the expression of 18 cytokine genes (IL-7, IL-10, TNFAIP8, SPP2, TNFAIP3, IFNB, CCL19, TNFAIP8L1, IL-16, CNTF, CXCL13, TNFAIP8L3, TNFSF13B, IL-34, TGFB1, TNFAIP2, CCL3, and ADIPOQ) and 39 cytokine receptor genes (CXCR7, CSF2RA, IL-1RL1, I-L1R2, IL-17RA, IFNAR1, IL-18RAP, IL-31RA, IL-9R, IL-18R1, IL-20RB, IL-21R, IL-2RG, IL-20RA, IL-4I1, LILRB1, TLR1, IL-17REL, LILRB5, TGFBR1, TLR6, TNFRSF13B, XCR1, TLR7, TNFRSF13C, TLR15 etc.) was also markedly upregulated by 2.03- to 8.41-fold and 2.08- to 9.12-fold, respectively, in chicken line 7.2 with p < 0.01 and fold [greater than or equal to] 2 (Supplementary Table S4, Figures 4 and 5).
A meta-analysis of data from two studies of IFNB-1a (CHAMPS and ETOMS) and one study of IFNB-1b (BENEFIT) for CIS supported the results of the individual studies; the risk of conversion from CIS to CDMS was reduced by 51 % with IFNB treatment versus placebo, and treatment with IFNB delayed the conversion from CIS to CDMS from 317 days to 363 days (Melo, Rodrigues, & Bar-Or, 2008).
(23.) IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group.
Several dermatological adverse events have been reported in the literature for MS patients treated with IFNB. Most of these events are related to the injection-site reaction and are usually mild-to-moderate local inflammatory reactions.
The current 'standard' disease-modifying therapies (DMTs) such as glatiramer acetate (GA) and interferon-beta (IFNB) have been clearly shown to reduce the short-term outcomes of relapse rate, disability scores and magnetic resonance imaging (MRI) evidence of disease.
The development of interferon beta-1a (IFN[beta]-1a), IFN[beta]-1b, and glatiramer acetate provided significant advances in the treatment of relapsing-remitting MS (RRMS; IFNB Multiple Sclerosis Study Group, 1993; Jacobs et al., 1996; Johnson et al., 1995; PRISMS Study Group, 1998).
M Sandberg-Wollheim (Lund, Sweden) presentation based on extensive safety data, suggested that long-term treatment with interferon (IFNB)-la does not increase malignancy risk in MS patients.
Trials have shown that to varying degrees, these first-line drugs improve clinical outcomes in MS patients (Table 2; IFNB Multiple Sclerosis Study Group, 1993; Jacobs et al., 1996; Johnson et al., 1995; PRISMS Study Group, 1998).
In the same vein, new onset RA is seen after a delay in MS patients who are otherwise being successfully treated with interferon beta (IFNB).
An estimated 85%-90% of patients receiving treatment with one of the three subcutaneously injected agents experienced at least one LISR in the phase 3 clinical trial of these drugs (European Study Group on Interferon beta-lb, 1998; IFNB Multiple Sclerosis Study Group, 1993; Johnson et al., 1995, 1998; Panitch et al., 2002; PRISMS Study Group, 1998).
Rudick et al examined this relationship in the context of the Phase III trial of interferon beta (IFNB)-1a given intramuscularly in order to evaluate criteria for 'treatment response'.